Suzy Huijghebaert1, Levi Hoste2,3, Guido Vanham4. 1. Independent Research Support, La Hulpe, Belgium. s.huijghebaert@scarlet.be. 2. Pediatric Pulmonology, Infectious Diseases and Immunology, Ghent University Hospital, Ghent, Belgium. 3. Primary Immunodeficiency Research Lab, Center for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, Ghent, Belgium. 4. Department of Biomedical Sciences, Institute of Tropical Medicine and University of Antwerp, Antwerp, Belgium.
Abstract
PURPOSE: Nasal irrigation or nebulizing aerosol of isotonic or hypertonic saline is a traditional method for respiratory or nasal care. A recent small study in outpatients with COVID-19 without acute respiratory distress syndrome suggests substantial symptom resolution. We therefore analyzed pharmacological/pharmacodynamic effects of isotonic or hypertonic saline, relevant to SARS-CoV-2 infection and respiratory care. METHODS: Mixed search method. RESULTS: Due to its wetting properties, saline achieves an improved spreading of alveolar lining fluid and has been shown to reduce bio-aerosols and viral load. Saline provides moisture to respiratory epithelia and gels mucus, promotes ciliary beating, and improves mucociliary clearance. Coronaviruses and SARS-CoV-2 damage ciliated epithelium in the nose and airways. Saline inhibits SARS-CoV-2 replication in Vero cells; possible interactions involve the viral ACE2-entry mechanism (chloride-dependent ACE2 configuration), furin and 3CLpro (inhibition by NaCl), and the sodium channel ENaC. Saline shifts myeloperoxidase activity in epithelial or phagocytic cells to produce hypochlorous acid. Clinically, nasal or respiratory airway care with saline reduces symptoms of seasonal coronaviruses and other common cold viruses. Its use as aerosol reduces hospitalization rates for bronchiolitis in children. Preliminary data suggest symptom reduction in symptomatic COVID-19 patients if saline is initiated within 48 h of symptom onset. CONCLUSIONS: Saline interacts at various levels relevant to nasal or respiratory hygiene (nasal irrigation, gargling or aerosol). If used from the onset of common cold symptoms, it may represent a useful add-on to first-line interventions for COVID-19. Formal evaluation in mild COVID-19 is desirable as to establish efficacy and optimal treatment regimens.
PURPOSE: Nasal irrigation or nebulizing aerosol of isotonic or hypertonicsaline is a traditional method for respiratory or nasal care. A recent small study in outpatients with COVID-19 without acute respiratory distress syndrome suggests substantial symptom resolution. We therefore analyzed pharmacological/pharmacodynamic effects of isotonic or hypertonicsaline, relevant to SARS-CoV-2 infection and respiratory care. METHODS: Mixed search method. RESULTS: Due to its wetting properties, saline achieves an improved spreading of alveolar lining fluid and has been shown to reduce bio-aerosols and viral load. Saline provides moisture to respiratory epithelia and gels mucus, promotes ciliary beating, and improves mucociliary clearance. Coronaviruses and SARS-CoV-2 damage ciliated epithelium in the nose and airways. Saline inhibits SARS-CoV-2 replication in Vero cells; possible interactions involve the viral ACE2-entry mechanism (chloride-dependent ACE2 configuration), furin and 3CLpro (inhibition by NaCl), and the sodium channel ENaC. Saline shifts myeloperoxidase activity in epithelial or phagocytic cells to produce hypochlorous acid. Clinically, nasal or respiratory airway care with saline reduces symptoms of seasonal coronaviruses and other common cold viruses. Its use as aerosol reduces hospitalization rates for bronchiolitis in children. Preliminary data suggest symptom reduction in symptomatic COVID-19patients if saline is initiated within 48 h of symptom onset. CONCLUSIONS:Saline interacts at various levels relevant to nasal or respiratory hygiene (nasal irrigation, gargling or aerosol). If used from the onset of common cold symptoms, it may represent a useful add-on to first-line interventions for COVID-19. Formal evaluation in mild COVID-19 is desirable as to establish efficacy and optimal treatment regimens.
Authors: A K Simonds; A Hanak; M Chatwin; Mj Morrell; A Hall; K H Parker; J H Siggers; R J Dickinson Journal: Health Technol Assess Date: 2010-10 Impact factor: 4.014
Authors: Wiwik Watanabe; Matthew Thomas; Robert Clarke; Alexander M Klibanov; Robert Langer; Jeffrey Katstra; Gerald G Fuller; Lester C Griel; Jennifer Fiegel; David Edwards Journal: J Colloid Interface Sci Date: 2006-11-15 Impact factor: 8.128
Authors: David A Edwards; Jonathan C Man; Peter Brand; Jeffrey P Katstra; K Sommerer; Howard A Stone; Edward Nardell; Gerhard Scheuch Journal: Proc Natl Acad Sci U S A Date: 2004-12-06 Impact factor: 11.205
Authors: Qiong Wang; Wenman Li; Ning Hu; Xi Chen; Ting Fan; Zhenyu Wang; Zhong Yang; Marcos A Cheney; Jun Yang Journal: Colloids Surf B Biointerfaces Date: 2017-04-13 Impact factor: 5.268
Authors: Michael Pfeifer; Santiago Ewig; Thomas Voshaar; Winfried Johannes Randerath; Torsten Bauer; Jens Geiseler; Dominic Dellweg; Michael Westhoff; Wolfram Windisch; Bernd Schönhofer; Stefan Kluge; Philipp M Lepper Journal: Respiration Date: 2020-06-19 Impact factor: 3.580
Authors: David Edwards; Anthony Hickey; Richard Batycky; Lester Griel; Michael Lipp; Wes Dehaan; Robert Clarke; David Hava; Jason Perry; Brendan Laurenzi; Aidan K Curran; Brandon J Beddingfield; Chad J Roy; Tom Devlin; Robert Langer Journal: QRB Discov Date: 2020-07-07
Authors: Danijela Štanfel; Livije Kalogjera; Sergej V Ryazantsev; Kristina Hlača; Elena Y Radtsig; Rashidov Teimuraz; Pero Hrabač Journal: Mar Drugs Date: 2022-05-17 Impact factor: 6.085
Authors: Rafael Gutiérrez-García; Juan C De La Cerda-Ángeles; Ariana Cabrera-Licona; Ivan Delgado-Enciso; Nicolas Mervitch-Sigal; Brenda A Paz-Michel Journal: Biomed Rep Date: 2021-12-15
Authors: I Pantazopoulos; A Chalkias; G Mavrovounis; I Dimeas; S Sinis; A Miziou; E Rouka; K Poulas; K Gourgoulianis Journal: Can Respir J Date: 2022-09-27 Impact factor: 2.130